ASX:CAR 13 May 2026

ASX:CAR·Automotive·Business·Investments·News

CAR Group Shareholder Shake-Up: Why the Carsales Owner Is Back in Focus

CAR Group Ltd published a notice late Thursday stating Mitsubishi UFJ Financial Group is no longer a substantial holder. A new First Sentier filing showed it holds 19.09 million shares, or 5.04% voting power, crossing Australia’s disclosure threshold. CAR shares last traded at A$26.17, down 2.75%.

May 15, 2026

ASX:CAR·Finance·Investment·Market Analysis·News

CAR Group (ASX:CAR) Starts Wednesday Under Pressure as Higher Rates Test Its Marketplace Premium

CAR Group closed at A$26.02 on Tuesday, down 1.33%, with trading volume over three times the average. The drop followed major tax changes in the federal Budget and last week’s RBA rate hike to 4.35%. CAR’s trailing P/E stands at 33.4. First Sentier/MUFG disclosed a 5.16% stake after the close.

May 13, 2026

Telix Pharmaceuticals Advances Connected Oncology Platform with Positive Phase 1 Glioblastoma Trial and Prostate Cancer Collaborations
May 28, 2026, 5:56 PM EDT. Telix Pharmaceuticals (ASX:TLX) announced full patient enrolment in its Phase 1 IPAX-2 trial for TLX101-Tx targeting glioblastoma, with no dose-limiting toxicities observed at highest doses. The firm also signed letters of intent to explore prostate cancer collaborations involving PSMA PET imaging, supporting its strategy to develop a connected oncology platform combining brain cancer therapy and prostate cancer imaging-based treatments. While encouraging for TLX101-Tx safety, the update does not alter focus on late-stage trials like IPAX BrIGHT or ProstACT GLOBAL. Telix faces risks including heavy reinvestment and an ongoing SEC subpoena linked to its prostate therapeutics segment. Analysts project Telix's revenue and earnings could reach A$1.2 billion and A$111 million by 2029, implying 22.7% annual growth and significant earnings expansion. Current stock price reflects potential for nearly 93% upside, though uncertainties remain.